COVID-19: FDA authorizes second booster for vulnerable groups
The U.S. Food and Drug Administration (FDA) on Tuesday, authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals.
According to the FDA, “A second booster dose of the Pfizer-BioNTech COVID-19 vaccine or Moderna COVID-19 vaccine may be administered to individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine.”
A second booster dose of the Pfizer-BioNTech COVID-19 vaccine to be administered to individuals 12 years of age and older with certain kinds of immunocompromise at least 4 months after receiving a first booster dose.
A second booster dose of the Moderna COVID-19 vaccine be administered to individuals 18 years of age and older with the same certain kinds of immunocompromise.
The FDA has determined that the known and potential benefits of a second COVID-19 vaccine booster dose with either of these vaccines outweigh their known and potential risks in these populations.
Xinhua
